Table 1 molecular targets of miR-338 during tumor progressions
From: Molecular interactions of miR-338 during tumor progression and metastasis
Study | Year | Type | Gene | Target | Samples | Function |
|---|---|---|---|---|---|---|
Liu [20] | 2018 | Lung | Circ-0001649 | miR-338-5p | 53 NT* A549, H358, H1299, and H1581 cell lines | Inhibited cell proliferation and migration |
Zhu [24] | 2020 | Renal | Circ-AKT1 | miR-338-3p | 70 NT 768-O, A498, ACHN, Caki-1, and OS-RC-2 cell lines | Induced cell proliferation, migration, and EMT |
Wang [28] | 2020 | Myeloma | Circ-0007841 | miR-338-3p | 41 patients and 41 healthy controls (plasma) H929 and OPM2 cell lines | Induced cell proliferation |
Du [32] | 2020 | Colorectal | Circ-RAE1 | miR-338-3p | 80 NT HCT116, SW620, HT29, and SW480 cell lines | Induced cell migration |
Xu [35] | 2020 | Lung | Circ-0000326 | miR-338-3p | 100 NT A549, SPC-A1, H1299, and H1975 cell lines | Induced tumor progression |
Shu [38] | 2020 | Thyroid | Circ-HIPK3 | miR-338-3p | 10 NT K1, CAL-62, and TPC-1 cell lines | Induced progression and invasion |
Liu [39] | 2020 | Liver | Circ-104566 | miR-338-3p | 87 NT SK-HEP-1, HLE, SNU449, Hep-3B, and Huh7 cell lines | Induced tumor progression |
Xiong [41] | 2019 | Glioma | Circ-SMO742 | miR-338-3p | 10 NT A172 and U-87MG cell lines | Induced cell proliferation |
Pu [43] | 2020 | Liver | Circ-0000092 | miR-338-3p | 40 NT Hep3B, LM3, MHCC97L, Sk-hep1, and HepG2 cell lines | Induced tumor progression |
Qian [47] | 2020 | Cervical | Circ-HIPK3 | miR-338-3p | 45 NT HeLa, CaSki, SiHa, C-33A, C-4I, and SW756 cell lines | Induced EMT |
Jin [48] | 2020 | Gastric | Circ-HIPK3 | miR-338-3p | 31 NT MGC803 and BGC823 cell lines | Induced cell migration |
Xiang [49] | 2020 | Osteosarcoma | Circ-CCDC66 | miR-338-3p | 12 NT SW1353 and U2OS cell lines | Induced tumor invasion |
Yang [50] | 2020 | Colorectal | Circ-0137008 | miR-338-5p | 30 NT HT29, HCT116, HCT8, LOVO, SW480, and SW620 cell lines | Inhibited cell proliferation and migration |
Yan [56] | 2017 | Esophageal | SNHG1 | miR-338-3p | 56 NT 6 primary cell culture | Induced cell proliferation |
Zhang [60] | 2019 | Neuroblastoma | SNHG1 | miR-338-3p | 33 NT SK-N-SH and SK-N-AS cell lines | Induced cell proliferation and migration |
Li [65] | 2019 | Colorectal | SNHG15 | miR-338-3p | 203 NT HCT116, SW620, LOVO, SW480, and 293Â T cell lines | Induced cell proliferation |
Zhang [66] | 2019 | Prostate | SNHG15 | miR-338-3p | LNCAP, DU145, and PC3 cell lines | Induced cell proliferation and EMT |
Liu [69] | 2018 | Ovarian | LINC00460 | miR-338-3p | 98 NT SKOV3, A2780, OVCAR, and HO-8910 | Increased cell proliferation and EMT |
Hu [70] | 2020 | Prostate | LINC00173 | miR-338-3p | 124 NT DU145, PC3, and LNCAP cell lines | Induced tumor cell progression |
Wan [71] | 2020 | Glioma | LINC00525 | miR-338-3p | U87, MO59K, U118, Hs683, and LN-18 cell lines | Regulated migration and EMT |
Lu [72] | 2020 | Gastric | LINC-00689 | miR-338-3p | 40 NT HGC-27, SGC-7901, MGC-803, and AGS | Induced cell growth and EMT |
Feng [74] | 2020 | Leukemia | NEAT1 | miR-338-3p | 32 patients 32 healthy controls KG-1, HL-60, THP-1, and U937 cell lines | Inhibited cell growth and migration |
Jing [76] | 2019 | Lung | CRNDE | miR-338-3p | 84 NT A549, H1299, SPCA1, and H358 cell lines | Induced tumor progression |
Song [79] | 2020 | Esophageal | BANCR | miR-338-3p | 40 NT KYSE450 and KYSE510 cell lines | Inhibited tumor progression |
Luan [80] | 2018 | Cervical | XLOC-006390 | miR-338-3p | 20 NT SiHa, HeLa, CaSki, C-41, and C-33A cell lines | Induced tumor progression |
Chen [82] | 2020 | Lung | SBF2-AS1 | miR-338-3p | 56 NT A549, H1650, and H1975 cell lines | Induced tumor growth |
Ji [83] | 2019 | Liver | DSCAM-AS1 | miR-338-3p | 48 NT HepG2, Hep3B, Huh7, and SMMC7721 cell lines | Induced tumor progression |
Li [85] | 2019 | Oral | OIP5-AS1 | miR-338-3p | 38 NT SCC9, SCC15, Ca9-22, and HSU3 cell lines | Increased cell proliferation, migration, colony formation, and in vivo growth |
Ma [89] | 2018 | Glioma | miR-338-5p | FOXD1 | 130 NT U251 cell line | Inhibited cell proliferation |
Hua [90] | 2017 | Cervical | miR-338-3p | MACC1 | 67 NT HeLa and CaSki cell lines | Inhibited cell proliferation |
Jia [91] | 2019 | Osteosarcoma | miR-338-3p | RUNX2, CDK4 | MG-63 and U2OS cell lines | Inhibited cell proliferation and migration |
Peng [96] | 2014 | Gastric | miR-338-3p | NRP1 | 41 NT SGC-7901, HGC-27, AGS, MKN-45, and N87 cell lines | Inhibited cell proliferation and migration |
Ding [98] | 2019 | Lung | miR-338-3p | NRP1 | 55 NT A549, HCC827, and H226 cell lines | Inhibited colony formation and cell migration |
Liu [99] | 2015 | Oral | miR-338-3p | NRP1 | 24 NT TCa-8113 and SCC-15 cell lines | Inhibited cell proliferation and invasion |
Song [112] | 2018 | Gastric | miR-338-3p | EPHA2 | AGS cell line | Inhibited proliferation and migration |
Niu [116] | 2019 | Ovarian | miR-338-3p | WNT2B | 54 NT SKOV3, A2780, and IOSE-80 cell lines | Induced cisplatin response |
Xue [120] | 2014 | Colorectal | miR-338-3p | SMO | 40 NT HT29, LOVO, Caco2, and SW-620 cell lines | Inhibited cell migration |
Huang [121] | 2011 | Liver | miR-338-3p | SMO | 36 NT Hep3B, SK-HEP-1, Huh7, Bel-7402, and SMMC-7721 cell lines | Inhibited tumor invasion |
Guo [124] | 2014 | Gastric | miR-338-3p | PREX2a | 53 NT AGS and BGC-823 cell lines | Inhibited tumor progression |
Chen [125] | 2013 | Neuroblastoma | miR-338-3p | PREX2a | 18 NT SH-SY5Y cell line | Inhibited cell proliferation and migration |
Besse [128] | 2016 | Glioblastoma | miR-338-5p | NDFIP1, PPP2R5a | 40 NT A172, T98G, and U87MG cell lines | Inhibited cell proliferation |
Liu [132] | 2019 | Lung | miR-338-3p | AKT | A549 cell line | Inhibited cell proliferation |
Sui [133] | 2017 | Thyroid | miR-338-3p | AKT3 | 48 NT 8505c, TPC-1, and SW1736 cell lines | Inhibited cell proliferation, migration, and in vivo growth |
Lu [137] | 2018 | Cervical | miR-338-3p | ATF2 | 30 NT Siha, HeLa, C33A, and Me180 cell lines | Inhibited autophagy |
Chu [141] | 2019 | Colorectal | miR-338-5p | PIK3C3 | 66 NT SW480 and HCT166 cell lines | Induced tumor invasion |
Zhang [145] | 2017 | Lung | miR-338-3p | IRS2 | 40 NT A549, H1299, SPCA1, and H358 cell lines | Inhibited cell proliferation and migration |
Wang [147] | 2015 | Liver | miR-338-3p | FOXP4 | 30 NT HepG2 and Hep3B cell lines | Inhibited cell proliferation |
Tong [152] | 2017 | Renal | miR-338-3p | SOX4 | 48 NT 786-O, ACHN, Caki-1, and Caki-2 cell lines | Inhibited colony formation and cell migration |
Jin [154] | 2015 | Breast | miR-338-3p | SOX4 | 32 NT MCF-7, MDA-MB-231, BT-549, and MDA-MB-453 cell lines | Inhibited colony formation, in vivo growth, and cell migration |
Huang [155] | 2015 | Gastric | miR-338-3p | ZEB2 | 20 NT AGS, MKN-45, and NCI-N87 cell lines | Inhibited EMT |
Lu [157] | 2019 | Colorectal | miR-338-3p | MACC1 | 15 NT SW480 and 293Â T cell lines | Inhibited cell proliferation and migration |
Zhang [158] | 2019 | Melanoma | miR-338-3p | MACC1 | 60 NT A375 and G361 cell lines | Inhibited cell proliferation and migration |
Zou [159] | 2018 | Colorectal | miR-338-3p | MACC1 | 98 NT SW480, SW620, HT29, HCT116, and SW1116 cell lines | Inhibited tumor progression |
Zhang [160] | 2019 | Ovarian | miR-338-3p | MACC1 | 105 NT | Inhibited cell proliferation and migration |
Shang [161] | 2016 | Glioma | miR-338-3p | MACC1 | 39Â T and 17Â N U251 and U87 cell lines | Induced cisplatin sensitivity |
He [166] | 2020 | Breast | miR-338-3p | ZEB1 | 148 NT MCF7 and HCC1937 cell lines | Inhibited cell proliferation and EMT |
Shan [167] | 2015 | Nasopharyngeal | miR-338-3p | HIF1A | 5 NT CNE-1, CNE-2, 5-8F, and 6-10B cell lines | Inhibited cell migration and proliferation |
Xu [168] | 2014 | Liver | miR-338-3p | HIF1A | 15 NT HepG2, SMMC-7721, BEK-7402, Hep3B, and Huh7 cell lines | Induced sorafenib response |
He [170] | 2020 | Lung | miR-338-3p | NFATc1 | 20 NT A549, H1650, SPCA-1, H460, H226, and H1299 cell lines | Inhibited cell proliferation |
Zhang [174] | 2019 | Bladder | miR-338-3p | ETS1 | 39 NT J82, 5637, and T24 cell lines | Inhibited cell proliferation and EMT |
Li [176] | 2018 | Glioma | miR-338-5p | TSHZ3 | 35 NT U87 and U251 cell lines | Increased invasiveness |
Wen [178] | 2015 | Ovarian | miR-338-3p | RUNX2 | 54 NT SKOV3, OVCAR3, and A2780 cell lines | Inhibited cell proliferation, migration, and in vivo growth |
Duan [181] | 2019 | Breast | miR-338-3p | MORC4 | 30 NT MCF7 and MDA-MB-231 cell lines | Inhibited cell migration |
Li [185] | 2013 | Gastric | miR-338-3p | SSX2IP | 66 NT SGC-7901, NCI-N87, BGC-823, AGS, KATO-III, SNU-1, MKN-28, and MKN-45 cell lines | Inhibited cell proliferation and in vivo growth |
Lei [191] | 2017 | Glioblastoma | miR-338-5p | EFEMP1 | 15 NT U251, A172, U-118, and U87 cell lines | Inhibited cell proliferation and migration |
Chen [197] | 2016 | Lung | miR-338-3p | ITGB3 | 115 NT A549, NCI-H292, NCI-H460, NCI-H446, and NCI-H1299 cell lines | Inhibited tumor invasion |
Li [200] | 2018 | Renal | miR-338-3p | KIFC1 | 58 NT 786-O, 769-P, and OS-RC-2 cell lines | Inhibited cell proliferation and migration |
Cao [202] | 2018 | Osteosarcoma | miR-338-3p | AHSA1 | 20 NT MG-63, Saos2, and HOS cell lines | Inhibited EMT and invasion |
Xiao [207] | 2018 | Liver | miR-338-3p | SPHK2 | 39T and 21N HepG2, SMMC-7721, and BEL7402 cell lines | Inhibited cell proliferation |
Zhang [209] | 2017 | Lung | miR-338-3p | SPHK2 | 34 NT H460, H1299, A549, SPC-A-1, and Calu-3 cell lines | Inhibited cell proliferation |
Han [216] | 2017 | Glioblastoma | miR-338-3p | PKM2 | U87, LN229, and SNB19 cell lines | Inhibited cell proliferation |
Zhang [217] | 2016 | Ovarian | miR-338-3p | PKM2 | HO-890, A2780, CoC1, CoC2, SKOV3, and Caov-3 cell lines | Inhibited cell proliferation |
Sun [220] | 2018 | Gastric | miR-338-3p | PTP1B | 12 NT MKN-45 and MGC-803 cell lines | Inhibited cell proliferation |